Home » Newsletters » BioWorld

BioWorld

April 18, 2011

View Archived Issues

Academia-Fueled R&D Helps Gilead's Move into Oncology

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

FDA Approvals in March

Phase I Clinical Trials Update: March 2011

Phase II Clinical Trials Update: March 2011

Phase III Clinical Trials Update: March 2011

Non-U.S. Clinical Trials & Regulatory Actions: March 2011

FDA Submissions, Approvals & Other Actions: March 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Big Rewards, Bigger Risks? The Truth About Antibodies

It's no secret that monoclonal antibodies (mAbs) have been hot biotech property for a while. Read More

IPO Pricing, Shares Offered: It's a Numbers Game